

RENALYTIX**AI**

PRESENTS

UT  H
LIFE SCIENCES
SUMMIT

VIRTUAL

THE CONVERGENCE OF
LIFE SCIENCES LEADERSHIP

NOVEMBER 9-11, 2020

NOW CFO is Thrilled to Support Bio Utah and The Life Science Summit!

Our NOW CFO consulting CFOs, Controllers, and Accountants can provide you with:

- Deal & Transactional Consulting
- Sale Side Due Diligence
- Transaction Prep
- Purchase Accounting
- Acquisition Integration
- Operational Accounting

Let's Meet Today!

Chris Badger

cbadger@nowcfo.com | [801.598.9390](tel:801.598.9390) | nowcfo.com



WELCOME



PRESIDENT'S MESSAGE

On behalf of BioUtah, I welcome you to the 11th annual Utah Life Sciences Summit! COVID-19 has driven business and personal lives since last March. The Utah Life Sciences Summit 2020 is no exception. We are virtual this year. That means you can join us from the comfort of your home, your office or anywhere you may be and benefit from the excellent content being presented.

COVID-19 figures strongly in our presentations this year. While a virtual format does not allow for gathering in person and the associated networking, it has afforded us the opportunity to attract speakers and Summit participants that may otherwise be unavailable due to travel costs and time commitments.

For instance, we have the privilege this year of hearing not only from two Center Directors at FDA at the heart of the FDA COVID-19 response, Dr. Jeff Shuren of CDRH and Dr. Peter Marks of CBER, we also have representatives of top vaccine companies participating on a panel. Our featured keynote speaker will be Paul Perreault, CEO of CSL Limited, an international vaccine company based in Australia. What most don't know is that Mr. Perreault makes Park City, Utah his permanent residence.

We are offering a robust range of topics that are current and associated with feedback we received from you. Included are panels on early stage investing, political landscape after the

election, and the state of innovation in Utah. Expert presenters on Inclusion and Diversity, employment law related to COVID-19 and the state of the industry are also scheduled to speak.

Most importantly, we will be revealing BioHive!! BioHive is an industry-wide branding initiative targeted to not only make our industry more cohesive, but tell our story in-state and around the country... indeed the world. Utah's life sciences profile is rising as our industry has grown faster since 2012 than in any other state. That is a story worth telling. BioHive is an initiative powered by BioUtah and supported by a host of public and private partners contributing financially to make it possible.

I would particularly like to recognize the efforts of Chris Gibson of Recursion Pharmaceutical and Jared Bauer of Ioniq Sciences who helped conceive and fund this initiative. Chris Gibson will chair the advisory board of BioHive and Jared will join that board. They bring an excitement and vision that has motivated all who have heard and understood what BioHive is and what it can accomplish.

We express appreciation to all of our sponsors who have made this event possible. A special thanks to RenalytixAI who stepped up as this year's Title Sponsor.

Please enjoy this Summit and look for our follow-up survey so you can provide feedback to help us make future Summits even better.

A handwritten signature in blue ink that reads "Kellyn Cullimore". The signature is fluid and cursive.

Kelvyn Cullimore
President & CEO, BioUtah

SPONSORS

THE 2020 UTAH LIFE SCIENCES SUMMIT
IS MADE POSSIBLE BY OUR GENEROUS SPONSORS

TITLE

RENALYTIX **AI**

PREMIER



PRESENTING



SESSION SPONSORS



CONTRIBUTING SPONSORS





65,000 people. One human hope.

BD is a purpose-driven company, *advancing the world of health™* by developing medical devices and sophisticated technologies that doctors, nurses, researchers and caregivers rely on to improve the lives of patients. As partners on the front lines, we've helped the world battle viral diseases for decades, from polio, smallpox and measles to HIV and the annual flu.

Today, the capabilities, expertise and global reach of BD are greater than ever, and in the face of COVID-19, we are mobilizing to equip our healthcare partners with a comprehensive suite of technologies and solutions that are essential to discovering more about the virus, diagnosing patients at scale and supporting patient care.

We're doubling down on what we do best—tapping our deep resources to help solve healthcare's biggest problems, working with urgency to innovate and ensure the front lines have what they need to address this crisis, and making an impact on lives around the world.

Diagnosis | Delivery | Discovery

bd.com/COVID-19



BD

Advancing the
world of health

JOINING THE SUMMIT

INSTRUCTIONS FOR JOINING UTAH LIFE SCIENCES SUMMIT

ACCESSING CONTENT

You may join the Summit via either the web app (desktop) or mobile app.

1. WEB APP (DESKTOP)

Visit **UtahLifeSciencesSummit.com** and click on the “Join Now” button. You’ll need to use the email address you registered with. If you are asked for an event invitation code when accessing the event, use **ulstj**. The webinar platform is most compatible with Google Chrome. You may experience performance issues using any other browser.

2. MOBILE APP

The **Whova** mobile app functions as a companion to the web app and may be accessed via the App Store or Google Play. Once installed, click “Find My Event/Conference” and search for “Utah Life Sciences Summit.” You’ll then need to login using the email listed on your registration.

VIEWING PANELS AND PRESENTATIONS

Panels and presentations are viewable in either the web app (desktop) or mobile app via the “Agenda.” You may add the presentations/panels you wish to attend to your schedule and view any session in progress. **Each presentation has its own link within the “Agenda.”** The live stream of presentations will not be continuous in the same session. To go from one presentation to another, you will need to click on each individual presentation in the “Agenda” at the time you wish to view it.


SUPPORT

If you have any problems with your registration, or accessing the webinar, you may contact 801.867.4061 or ulss2020@bioutah.org.

A BETTER WAY

At ATL, we believe there's a better way to bring medical devices to market. We use an engineer-to-engineer approach to develop custom interconnect solutions for medical devices that improve the quality of one's life.


ENGINEER-TO-ENGINEER



WE BEGIN EVERY PROJECT WITH THE END IN MIND.

Engineer-to-engineer means you work directly with our hands-on engineering team to design, develop, and manufacture your interconnect device.

CUSTOMER INTERCONNECT SOLUTIONS



WE USE A HOLISTIC APPROACH.

Your innovative device requires an interconnect that can keep up. We'll help you design your interconnect solution into your device, so you don't have to use a sub-optimal off-the-shelf solution.



AGENDA

DAY
1

OPENING SESSION

HOT TOPICS IN LIFE SCIENCES

MONDAY, NOVEMBER 9, 2020 » 8:30 AM - NOON

SPONSORED BY



8:30 AM



WELCOME

KELVYN CULLIMORE – PRESIDENT/CEO, BIOUTAH

8:35 AM




CHAIRMAN'S REMARKS

BRANDI SIMPSON – BOARD CHAIRMAN, BIOUTAH

8:45 AM

DEVELOPING A COVID-19 VACCINE

- DR. WILLARD DERE – AVP RESEARCH, HEALTH SCIENCES, U OF U
- DR. RICK NETTLES – VP MEDICAL AFFAIRS, JANSSEN INFECTIOUS DISEASES AND VACCINES
- DAVE HERING – REGIONAL PRESIDENT FOR NORTH AMERICA- VACCINES, PFIZER
- CLEMENT LEWIN – ASSOCIATE VICE PRESIDENT, SANOFI
- DR. GREGG SYLVESTER – CHIEF MEDICAL OFFICER, SEQIRUS



9:45 AM



A VIEW OF THE LIFE SCIENCES INDUSTRY

KYLE FINEGAN – VP HEALTHCARE COVERAGE GROUP, JP MORGAN

10:15 AM



CDRH RESPONSE TO COVID -19 AND BEYOND

DR. JEFF SHUREN – CENTER FOR DEVICES AND RADIOLOGICAL HEALTH, FDA

11:00 AM



FDA'S APPROACH TO VACCINE DEVELOPMENT AND EVALUATION

DR. PETER MARKS – CENTER FOR BIOLOGICS EVALUATION AND RESEARCH, FDA

11:45 AM

WHAT IS BIOHIVE?

- CHRIS GIBSON – CEO, RECURSION PHARMACEUTICAL
- JARED BAUER – CEO, IONIQ SCIENCE
- KATELIN ROBERTS – CEO, LINELOGIC



MONDAY AFTERNOON

OPERATING IN A COVID ENVIRONMENT

MONDAY, NOVEMBER 9, 2020 » 1:00 PM - 4:00 PM

SPONSORED BY



1:00 PM

GLOBAL PANDEMIC: PRESENT AND FUTURE BUSINESS IMPACTS

- TARA SAUCEDO – SR. DIRECTOR OF OPERATIONS, STRYKER
- KEN ELIASSEN – VP DELIVERY SYSTEMS OPERATIONS, EDWARDS LIFESCIENCES
- FRANK MAGUIRE – CEO, FOLDAX
- MICHAEL KIMBALL – VP GX R&D, TEVA
- JEFF NELSON – CHAIRMAN, NELSON LABS



MODERATOR

2:00 PM

EMPLOYMENT LAW CONSIDERATIONS RELATED TO COVID-19


- MATT DURHAM – EMPLOYMENT LAW & COVID-19, STOEL RIVES
- LAUREN SHURMAN – PARTNER, STOEL RIVES



3:00 PM

EARLY-STAGE CAPITAL RAISING IN A COVID ENVIRONMENT

- LISA DUNLEA – CEO, XABLECATH/MGR. DIR., VITA CAPITAL PARTNERS
- KEENAN MCCOLLAM – DIRECTOR CAPITAL RAISE ADVISOR, NOW CFO
- GEETA VEMURI – MANAGING PARTNER, AGENT CAPITAL
- JULIE GRANT – GENERAL PARTNER, CANAAN PARTNERS



DAY

2

TUESDAY MORNING

OUR CHANGING LANDSCAPE

NOVEMBER 10, 2020 » 9:00 AM - NOON

SPONSORED BY



9:00 AM

THE ELECTION IS OVER – NOW WHAT?

- KELVYN CULLIMORE – CEO, BIOUTAH
- JEFF KIMBELL – CEO, KIMBELL & ASSOCIATES
- JEFF RICCHETTI – PRESIDENT, RICCHETTI, INC.



10:00 AM



DIVERSITY & INCLUSION – TRANSFORMATIVE CHANGE

SARA JONES – CEO, INCLUSIONPRO; CO-FOUNDER, WOMEN TECH COUNCIL

11:00 AM

UTAH LIFE SCIENCES: GROWING AN INNOVATION CULTURE

- KEITH MARMER – CHIEF INNOVATION OFFICER, PIVOT CENTER, U OF U
- CHANDANA HAQUE – EXECUTIVE DIRECTOR, ALTITUDE LABS
- ALAN MATHESON – EXECUTIVE DIR., POINT OF THE MOUNTAIN LAND AUTHORITY
- CLARK CAHOON – TECH & INNOVATION ADVISOR, SALT LAKE CITY CORP.
- COLBY JENKINS – DIRECTOR, ATWOOD INNOVATIONS PLAZA



TUESDAY AFTERNOON

NETWORKING

NOVEMBER 10, 2020 » NOON - 5 PM

SPONSORED BY




12:00 PM

NETWORKING GROUPS & EXHIBITOR PRESENTATIONS

1:00 PM

BECOMING PART OF BIOHIVE

- KATELIN ROBERTS – LINELOGIC CEO
- JARED BAUER – IONIQ SCIENCES





WEDNESDAY MORNING
 BUSINESS MEETING, AWARDS AND KEYNOTE
 NOVEMBER 11, 2020 » 8:00 AM - 1:00 PM

SPONSORED BY



8:00 AM NETWORKING AND EXHIBITOR PRESENTATIONS

11:00 AM BIOUTAH BUSINESS MEETING

BIOUTAH AWARDS PRESENTATIONS

- FRIEND OF INDUSTRY AWARD:
ERIN MENDENHALL, MAYOR, SALT LAKE CITY
- ENTREPRENEUR OF THE YEAR:
CHRIS GIBSON, CEO, RECURSION PHARMACEUTICAL
- INNOVATION IMPACT AWARD:
SPECTRUM SOLUTIONS, BILL PHILLIPS, COO
- EXECUTIVE OF THE YEAR:
RANDY RASMUSSEN, CO-FOUNDER, BIOFIRE DIAGNOSTICS
- LIFETIME ACHIEVEMENT AWARD:
GARY CROCKER, PRESIDENT, CROCKER VENTURES

11:45 AM



KEYNOTE SPEAKER – INNOVATING IN BIOTECH: THE PROMISES, POTENTIAL AND PITFALLS

PAUL PERREAULT – CEO, CSL LIMITED

Q&A WITH PAUL PERREAULT

WEDNESDAY AFTERNOON
 REGULATORY, COMPLIANCE AND QUALITY
 NOVEMBER 11, 2020 » 1:00 PM - 4:30 PM

SPONSORED BY



1:00 PM

MDR PANEL OF EXPERTS

- MICHAEL RINCK – MD PROMEDT
- NICOHL ASHER – CGH & ASSOC, FORMERLY WITH SGS
- KELLI OBORN – TECHNICAL SPECIALIST, VASCULAR DEVICES BSI
- CHRIS PHILLIPS – DIRECTOR, REGULATORY/CLINICAL AFFAIRS, FLUIDX MEDICAL
- KRISTEN KANACK – SVP, MOLECULAR BIOFIRE R&D AND PROGRAMS, BIOFIRE DX
- VANESSA LACEY – REGULATORY AUDITOR, DEKRA



2:30 PM



RISK MANAGEMENT – WHAT THE STANDARDS FAIL TO TELL YOU


- RAI CHOWDHARY – CEO, KPI SYSTEMS

3:30 PM

FDA GUIDANCE ON EMERGENCY USE AUTHORIZATION

- SPENCER WALKER – DIR. REGULATORY AFFAIRS, U OF U HEALTH SCIENCES
- EITAN BERNSTEIN – ASSOCIATE, LATHAM AND WATKINS





SCIENCE WILL BRING

US BACK TO NORMAL.



See the progress at PhRMA.org/coronavirus

PhRMA
RESEARCH • PROGRESS • HOPE

PRESENTERS

SUMMARY BIOGRAPHIES



NICHOHL ASHER

PRESIDENT

CGH & ASSOCIATES, LTD

Nichol is president of CGH & Associates, LTD. She has over 20 years of experience in the medical device and pharmaceutical industry. Nichol has held Senior Regulatory and Quality positions with several Chicago area medical device companies. Nichol worked for a leading Notified Body for over 10 years as a qualified lead auditor and most recently was a certification decision maker for ISO 13485 and MDD. Her expertise lies in global regulatory compliance, regulatory strategy and quality system implementation. She has written and managed numerous submissions to U.S. and international regulatory agencies, developed global regulatory strategies for medical devices and implemented full Quality Management Systems. Nichol graduated with a Bachelor of Science degree from the University of Illinois, Chicago.



JARED BAUER

CEO

CIBUS BIOTECHNOLOGIES INC., IONIQ SCIENCES

Jared Bauer is the CEO of both Cibus Biotechnologies Inc. (point-of-care diagnostics), and IONIQ Sciences (early stage cancer testing). Mr. Bauer also serves as the Chairman of the BioUtah SLC Biotech Initiative Advisory Committee where he is leading an effort to brand the Utah Life Science community and expand its global reach, and as a trustee for The Oliver Fund, a non-profit he co-founded. In 2012, Mr. Bauer founded Exuro Medical and acquired BurnFree Products. In just two years with a focus on sustainable revenue generation, he led the Exuro Medical team to expand BurnFree distribution to 58 countries, managing regulatory processes, re-working quality systems and making BurnFree the second largest burn treatment product line in the world. Recently Mr. Bauer also served as an adjunct professor of entrepreneurship at the LDS Business College.



EITAN BERNSTEIN

LATHAM AND WATKINS
ASSOCIATE

Eitan Bernstein is an associate in the Washington, D.C. office of Latham & Watkins LLP. He focuses his practice on regulatory matters involving the Food and Drug Administration (FDA) and transactions involving the life sciences industry. He advises on matters involving pre-market development strategies, FDA submissions, regulatory inspections, and product recalls, and has assisted in the review of clinical trial agreements for both pharmaceutical and medical device companies.



CLARK CAHOON

TECHNOLOGY & INNOVATION ADVISOR
SALT LAKE CITY CORPORATION DEPARTMENT
OF ECONOMIC DEVELOPMENT

Clark is the Technology & Innovation Advisor at Salt Lake City’s Department of Economic Development, working to enact Mayor Mendenhall’s Healthcare Innovation Initiative. Prior to this position Clark was Governor Herbert’s Life Science sector lead, where he drove strategic initiatives, published industry reports, supported corporate recruitment efforts, and worked with startups to connect them to vital resources that help put Utah on the map as a biotech and innovation hub. He spends his free time camping and hiking through Utah’s mountains and deserts, playing basketball or reading a good book.



STOEL RIVES
IS A PROUD SPONSOR OF

**The BioUtah
Life Science Summit**

www.stoel.com | [@stoelrives](https://twitter.com/stoelrives)

**THE UTAH INDUSTRY AND
INNOVATION CENTER**

proudly supports

**BIOUTAH
AND
UTAH’S LIFE SCIENCES INDUSTRY**

- Creating sustainable advantages by aligning business interests
- Bringing together key stakeholders to spur economic growth

SBIR Services

- All levels of proposal support to receive non-dilutive funding through federal Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs
- A success rate nearly double the national average



**Utah Governor's Office of
Economic Development**
INDUSTRY AND INNOVATION CENTER

LIFE SCIENCES IN SLC

We are leading through crisis, together. Salt Lake City is building a world-class Healthcare Innovation Center -- intentional space for more incubator, office, and wet lab locations where startups can grow and scale with ease. For more information reach out to Technology and Innovation Advisor Clark Cahoon at clark.cahoon@slcgov.com or visit slc.gov/ed.



1

FIRST IN NATION
FOR ACADEMIC
LIFE SCIENCES
R&D GROWTH

2

SECOND IN NATION
FOR MEDICAL DEVICE
EMPLOYMENT
CONCENTRATION

FIND A NEW
PATH



“The life sciences industry is critical to fueling healthcare innovations, which will, in turn, strengthen our public health and local economy.”

—Salt Lake City Mayor Erin Mendenhall



SLC.GOV/ED



RAI CHOWDHARY

CEO
THE KPI SYSTEM

Rai is an entrepreneur, coach, inventor, and author. The KPI System is his eighth startup and is focused on enabling performance improvement with a client list spanning startups to established Fortune 50 companies. Rai has a passion for risk management and believes we are rather naive when it comes to managing risk. His research and work on how we can get ahead in dealing with risk will culminate in his fifth book.



KELVYN CULLIMORE

PRESIDENT
BIOUTAH

Kelvyn served for 25 years as president and CEO of Dynatronics Corporation, a publicly traded medical device manufacturer. Kelvyn served on the board of the Medical Device Manufacturers Association in Washington D.C. and on the board of trustees for the Utah Technology Council. From 2005 to 2018, he served as the first mayor of Cottonwood Heights.



BIOFIRE DIAGNOSTICS
Manufacturing Facility / Salt Lake City, Utah





WILLARD DERE

ASSOCIATE VICE PRESIDENT FOR RESEARCH,
UNIVERSITY OF UTAH HEALTH SCIENCES
UNIVERSITY OF UTAH

Dr. Dere has extensive experience in clinical research during his 25 year stint in the biopharmaceutical industry. The experience was complemented by substantive regulatory and drug safety experience during that time. At the University of Utah, Dr. Dere serves as the Executive Director of the Program in Personalized Health and Co-Director of the Utah Center for Clinical and Translational Science.



LISA DUNLEA

CEO/MANAGER DIRECTOR
XABLECATH/VITA CAPITAL PARTNERS

Lisa Dunlea has over 25 years of life science operating and investment experience, as an executive at VC funded companies and a VC investor serving on numerous boards. She is currently XableCath's CEO. Her experience includes fund raising, sale and marketing, R&D, clinical trials, and managing investments to liquidity. Previously, she was an aerospace engineer. Lisa was a Kauffman Fellow, has an M.S. in Engineering from FIU, and M.B.A from Wharton.



Formerly Known as AdvancedCFO



MATT DURHAM

EMPLOYMENT LAW & COVID-19
STOEL RIVES

Matt Durham is a partner in Stoel Rives’ Labor & Employment group and previous chair of the group. A frequent media commentator and blogger at the World of Employment blog, Matt defends employers in Utah and throughout the west in disputes in state and federal courts and administrative agencies involving employment discrimination, harassment, wrongful termination, wage and hour, drug testing, leave, noncompetition, workplace torts, benefits and labor/occupational safety issues. In addition to litigation, Matt routinely advises employers in Utah and elsewhere on developing and implementing personnel policies and complying with state and federal employment laws.



KYLE FINEGAN

VP HEALTHCARE COVERAGE GROUP
JP MORGAN

Kyle Finegan joined J.P. Morgan in 2014 and is currently a Vice President in the Healthcare Investment Banking group, with a focus on Life Science Tools and Diagnostic companies. His experience includes corporate finance and mergers and acquisitions advisory, and equity and debt financings for a variety of healthcare clients. Prior to joining J.P. Morgan, Kyle worked in investment banking at a boutique advisory firm, Croft & Bender. Kyle is a graduate of the University of Georgia and Goizueta Business School at Emory University.



KEN ELIASSEN

VP DELIVERY SYSTEMS OPERATIONS
EDWARDS LIFESCIENCES

Experienced Vice President of R&D and Operations with a demonstrated history of working in the medical device industry. Skilled in DMAIC, Design Control, Verification and Validation (V&V), Medical Devices, and PTC Creo. Strong development & operations professional with a Bachelor of Science (B.S.) focused in Business Administration, Management and Operations.



CHRIS GIBSON

CO-FOUNDER AND CEO
RECURSION PHARMACEUTICAL

Recursion Pharmaceuticals is a biotech company leveraging the latest in automation, artificial intelligence and biology to do drug discovery at scale. Chris developed the technology and approach underlying Recursion as part of his MD/PhD graduate work in the lab of co-founder, Dr. Dean Li, at the University of Utah. Chris left medical school to transform this technology into the rapidly growing company it is today. Chris graduated from Rice University with degrees in bioengineering and managerial studies and from an intense entrepreneurship course at Stanford GSB.



JULIE GRANT
GENERAL PARTNER
CANAAN PARTNERS

Julie Grant is a General Partner at Canaan, a tech and healthcare venture capital fund with \$5B assets under management. She primarily leads investments and company formation efforts in biopharmaceuticals. Since joining Canaan in 2013, Julie has incubated, financed, and supported investments in multiple new ventures including Day One where she was founding CEO, Synthekine, Nocion, Protagonist (PTGX), Cellular Research (Acquired by Becton Dickinson), Dermira (DERM), Labrys Biologics, CytomX (CTMX), Unchained Labs, Chrono Therapeutics, Genome Medical,


Glooko, Vineti and Truveris. Prior to joining Canaan, Julie worked at Genentech in multiple capacities across development and commercial. She earned a B.S. in Molecular Biophysics and Chemistry from Yale, a MPhil BioScience Enterprise from Cambridge, and MBA from Stanford.



CHANDANA HAQUE
EXECUTIVE DIRECTOR
ALTITUDE LAB

Chandana Haque is a product strategist with over a decade of experience operating life science startups. Chandana earned her B.S. at Carnegie Mellon and her MBA from UC Berkeley—Haas School of Business where she focused her graduate

Johnson & Johnson



LEGACY ELITE MEMBER



work in strategic finance and innovation. While earning her degree, she worked in venture capital and researched novel approaches to innovation. Chandana has developed a passion for coaching founders and an appreciation for the systemic challenges underrepresented founders face.



DAVID HERING

REGIONAL PRES. OF VACCINES-NO. AMERICA
PFIZER

Before joining Pfizer, David held various positions at Novartis Vaccines, Keystone Strategy, Merck, and 3M. At Novartis Vaccines, David acted as Head of the North America Region overseeing a portfolio of four vaccine assets in Meningitis and Travel. In this role, David was responsible for the

launch of Bexsero®, Novartis’s licensed meningococcal B vaccine. He also led the transition of Novartis Vaccines to GSK. During the Ebola epidemic, ran a unified Ebola task force response and coordinate all activities across several divisions of the company. He earned a bachelor of science from Cornell University and an MBA from Harvard Business School.




COLBY JENKINS

DIRECTOR
ATWOOD INNOVATION PLAZA, DIXIE STATE
UNIVERSITY

Jenkins, a combat veteran and U.S. Army Special Forces Green Beret, has worked on Capitol Hill for the U.S. Senate and Pentagon. He has taught as an



Solutions in Sight®



A Utah Based Market Leader in X-ray Imaging Components

www.vareximaging.com

TITLE SPONSOR

RENALYTIX **AI**



Trailblazing the frontier of digital biology

From an idea generated in the labs at the University of Utah to the leader in technology-enabled drug discovery. In a few short years, Recursion has built a world-class digital biology company headquartered in downtown Salt Lake City:

Four clinical-stage programs and five pre-clinical candidates

Industry-leading partnership with Bayer Pharmaceuticals in fibrotic disease

Approximately \$450M raised from local, national and international investors

World's largest dataset of images of human cellular biology

The next generation of biotech leaders with Altitude Lab

Learn more at [RecursionPharma.com](https://www.RecursionPharma.com)

adjunct professor at George Washington University's Graduate School of Political Management and worked at Google Headquarters as a program manager. Most recently, Jenkins served as the director of operations for the Pentagon's Silicon Valley Innovation Office, known as the Defense Innovation Unit.



SARA JONES
CEO, INCLUSIONPRO; CO-FOUNDER, WOMEN
TECH COUNCIL
BIOFIRE DIAGNOSTICS
Sara Jones creates global diversity and inclusion strategies to elevate inclusive work cultures. She has advocated throughout her career for the

benefits of greater diversity in our companies, boardrooms, and circles of power. Sara is an inclusionist, working to amplify inclusion as a core leadership skill. Sara is a consultant for Medsential and, a Founder of Women Tech Council (WTC).



KRISTEN KANACK
SENIOR VICE PRESIDENT
BIOFIRE/BIOMERIEUX
Dr. Kanack holds Bachelor of Science, Master of Science, and PhD degrees in Medical/Molecular Microbiology. She has more than 20 years of experience in Microbiology and more than 12 years of experience the development lifecycle of IVDs for infectious disease. She

stryker

We improve
lives

Customers and patients are at the heart of everything we do.

We're a driven company where people work with passion, purpose and integrity to deliver remarkable, innovative products for customers and patients.

Find out more about how you can make a difference at careers.stryker.com



currently leads Molecular R&D and Programs for BioFire Diagnostics/bioMérieux, which spans the global development, validation, registration, and postmarket surveillance of the BioFire product line of user-friendly syndromic sample-to-answer PCR-based diagnostic panels.



MICHAEL KIMBALL

VICE PRESIDENT GX R&D
TEVA

Michael has 28 years of experience in pharmaceutical product development. He is inventor on several patents related to drug delivery and is the author of a book chapter on the scale-up of topical products. Michael has been an invited speaker at

numerous industry conferences and holds a B.S. in Mechanical Engineering from the University of Utah and an M.S. in Mechanical Engineering from UC Berkeley, where he attended as a Fellow of Tau Beta Pi.



JEFFREY KIMBELL

CEO/PRESIDENT

JEFFREY J. KIMBELL & ASSOCIATES

Jeffrey J. Kimbell, President of Jeffrey J. Kimbell & Associates, represents over 50 clients in the life sciences community seeking legislative and policy remedies in Washington. Founded in 1998, the fourteen person firm provides strategic solutions to hand-selected clients seeking creation, modification, or proper implementation of public law. Mr. Kimbell has contributed to or been interviewed by a host of trade and global news publications and television programs including Bloomberg's Business News, Time Magazine, The New York Times, Reuters, The Washington Post, The Bureau of National Affairs (BNA), Congressional Quarterly, Forbes, MX Magazine, Scripps-Howard, Roll Call, Politico, The Food & Drug Law Journal, and The Hill. Mr. Kimbell has testified before the U.S. Congress and spoken before numerous industry groups, boards of directors, scientific advisory boards, associations, and educational institutions, including Harvard, Georgetown and Stanford Business Schools, Columbia University School of Public Health, the Young Presidents' Organization, AdvaMed, the OCTANe Medical Device & Investor Forum, AAOS Chicago Ophthalmology Summit, AECOS, and many others. In January of 2001, Mr. Kimbell was named to President George W. Bush's Transition Team Advisory Committee for the U.S. Department of Health and Human Services (HHS) and assisted a host of Presidential appointees through their confirmation process in the U.S. Senate. He was the only consultant to serve on the Committee.





VANESSA LACEY
REGULATORY AUDITOR
DEKRA

Vanessa earned her BS in Molecular and Cellular Biology from Cornell University and her PhD in Biomedical Sciences from UCSD. Upon graduation, she worked on ThermoFisher’s development team as a Staff Scientist to validate the OncoPrint Dx Test on the PGM Dx Next Generation Sequencing platform. Her auditing career began at TUV, and she is currently a regulatory auditor for DEKRA, focusing primarily on IVD devices.



CLEMENT LEWIN
ASSOCIATE VICE PRESIDENT
SANOFI


Clement Lewin is Associate Vice President Head BARDA Office and New Vaccine Stakeholder Engagement responsible for managing the company’s relationship with the Biomedical Advanced Research and Development Authority focusing on pandemic preparedness as well as COVID-19 and supports engagement with external stakeholders. He has been in the vaccines industry for 25 years and joined Sanofi Pasteur in 2015. Clem obtained his BSc and PhD from the University of London and an MBA from Cornell University.

Join Us in the Fight Against Infectious Diseases—Including COVID-19!

Now Hiring in Every Department

Science | Manufacturing | Software/IT | Engineering

www.biofire.com/company/career





FRANK MAGUIRE

CEO
FOLDAX

CEO at Foldax, developer of world’s-first Tria synthetic heart valve. 35 + years experience in Med-Tech, came to SLC as early employee of Symbion, developing the Jarvik Artificial Heart. Started career with Baxter, held executive positions with Bard and Edwards Lifesciences. Most recently CEO of UK publicly traded Aortech with headquarters in Glasgow and factories in Australia and Minnesota.



KEITH MARMER

CHIEF INNOVATION OFFICER
PARTNERS FOR INNOVATION, VENTURES,
OUTREACH & TECHNOLOGY (PIVOT) CENTER AT
THE UNIVERSITY OF UTAH

Keith is the chief innovation officer of the Partners for Innovation, Ventures, Outreach & Technology (PIVOT) Center at the University of Utah. His strong leadership skills come from 30 years of experience as an inventor, entrepreneur and investor. Keith’s passion for innovation has helped countless ideas get the momentum they need to succeed. He has three patents, launched four companies, and helped entrepreneurs raise more than \$500 million in investment capital. An avid skier, hiker and traveler, he has visited almost all 50 states, and more than forty countries.



PETER MARKS

DIRECTOR, CENTER FOR BIOLOGICS EVALU-
ATION AND RESEARCH
U.S FOOD AND DRUG ADMINISTRATION

Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in January 2016.



ALAN MATHESON

EXECUTIVE DIRECTOR
POINT OF THE MOUNTAIN STATE LANE
AUTHORITY

Alan Matheson oversees planning and development of The Point--700 acres of state-owned land near Point of the Mountain, one of the premier economic development opportunities in Utah’s history. Matheson previously served as Executive Director of the Utah Department of Environmental Quality, Senior Environmental Policy Advisor to Governor Herbert, State Planning Coordinator, and Executive Director of Envision Utah. Matheson holds an A.B. from Stanford University and a J.D. from the UCLA School of Law.



UNDERSTAND. INNOVATE. DELIVER.

Merit Medical's mission is to be the world's most customer-focused healthcare company by understanding customers' needs and innovating and delivering a diverse range of products that improve the lives of people, families, and communities throughout the world.

**FOUNDED
IN 1987**

- // Global Headquarters in South Jordan, Utah
- // 9 Manufacturing Locations Worldwide
- // 5,959 Employees
- // MMSI \$2.73B Market Cap



Merit Vascular / Merit Spine / Merit Oncology / Merit Endoscopy

merit.com



KEENAN MCCOLLAM

DIRECTOR CAPITAL RAISE ADVISOR
NOWCFO

Keenan McCollom is the director of NOW CFO's capital raise advisory division and is an experienced investment banker and private equity professional. Keenan has extensive experience in numerous industries including tech, healthcare, consumer product and renewable energy. NOW CFO's capital raise advisory team works with early to growth stage companies to help them raise venture, PE, mezzanine and other forms of private capital.



JEFF NELSON

CHAIRMAN
NELSON LABS; JEFFERY R. & KATIE C. NELSON
FOUNDATION

Jeffery has worked in the contract testing space for more than 30 years, most recently as Chairman of Nelson Laboratories. Jeffery has set the course for Nelson Laboratories to become the global leader in laboratory testing services. Jeffery was recognized as the Utah Technology Council CEO of the Year in 2009 and is the recipient of an Honorary Doctor of Humane Letters Degree from Salt Lake Community College, where he has regularly contributed to curriculum design in health and science programs. Jeffery has served on several boards including BioUtah, Utah Shakespeare Festival, Utah STEM Action Center, Talent Ready Utah, J&J Kilmer Conference Industrial Advisory, and the U of U Bioengineering Industrial Advisory. Jeffery and his wife Katie also give back to the community through their foundation. Jeffery received a Bachelor of Science degree from the University of Utah in Microbiology and a Master in Business Administration degree from Westminster College. Additionally, he is a Specialist Microbiologist (SM) with the National Registry of Certified Microbiologists (NRCM) and a Certified Scrum Master (Scrum Alliance). Jeffery currently lives in South Jordan with his wife Katie and two children, Alex and Riley.



AdvaMed

Advanced Medical Technology Association



RICK NETTLES, MD

VICE PRESIDENT MEDICAL AFFAIRS
VP MEDICAL AFFAIRS, JANSSEN INFECTIOUS
DISEASES

Rick Nettles, Vice President of Medical Affairs, Janssen Infectious Diseases, leads the US Infectious Diseases Medical Affairs team, which enables Janssen to bring critical, market-leading therapies to people living with HIV. He and his team also work closely with global R&D colleagues in support of research that spans both vaccines and therapeutics. He is a key spokesperson for Johnson & Johnson on the company's response to the Coronavirus pandemic. Rick has more than 15 years of experience in the pharmaceutical industry. Prior to joining Johnson & Johnson in 2011, he

held various positions with Bristol Myers Squibb, including research and development leadership roles in virology for the company's Discovery Medicine, Clinical Pharmacology and Global Clinical Research Organizations. Rick holds a Bachelor of Science Degree from the University of Notre Dame. After receiving his medical degree from Duke University, Rick completed his internal medicine residency at Duke University Medical Center and his infectious diseases fellowship from Johns Hopkins University. He served as Assistant Professor, Medicine, in the Infectious Diseases department at Johns Hopkins, where he attended in the Johns Hopkins HIV Clinic.

Patients. Our mission for life.

We have all chosen to belong to a community with a single passion: helping patients live longer, healthier and more productive lives. But within us beats a shared desire to do more. We are driven by the intrinsic certainty that there is always a better way.

Big ideas with the power for change are the cornerstone on which Edwards Lifesciences was founded, and continues to drive how we transform patient care today. So when we ask ourselves, "Is it possible?" – the answer must be yes. Because together, we're doing even more than helping patients. *We're on a mission to change lives.*

Edwards, Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2018 Edwards Lifesciences Corporation. All rights reserved. PP--US-1611 v2.0

Edwards Lifesciences • One Edwards Way, Irvine CA 92614 USA • edwards.com





KELLI OBORN

TECHNICAL SPECIALIST AND SCHEME MANAGER
BSI

Kelli has a BS and MS in Mechanical Engineering from the UofU, over twelve years of medical device design experience, and multiple patents for vascular devices and prosthetics. As a Technical Specialist and Scheme Manager on BSI's Vascular Team, she has 2 years' experience reviewing vascular device technical data. Prior to this, Kelli worked for Bard/BD as a Staff R&D Engineer designing vascular devices for five years and has additional medical device industry experience.



CHRISTOPHER PHILLIPS

DIRECTOR, REGULATORY AFFAIRS AND CLINICAL
AFFAIRS

FLUIDX MEDICAL TECHNOLOGY

Chris is a recognized leader with extensive experience in Medical Device Regulatory Affairs, Clinical Affairs, and Quality Assurance. Chris has brought innovative medical devices to market in the USA, Europe, and other global markets for large and small companies. Chris currently leads Fluidx Medical's regulatory and clinical efforts, navigating the intersection of these two critical areas. Chris completed a Master of Science degree in Regulatory Affairs and holds RAPS' RAC (US) and ASQ's CBA certifications.



PAUL PERREAULT

CEO
CSL LIMITED

Paul Perreault was appointed Chief Executive Officer (CEO) and Managing Director of CSL Limited in July 2013. Since then, CSL has grown to become the fifth largest biotechnology company in the world with 27,000+ employees providing lifesaving products to 100+ countries. Paul, who brings more than 30 years of experience in the global healthcare industry, joined CSL in 2004 when CSL Limited acquired Aventis Behring. Prior to his current role, Paul served as CSL Behring's President and Executive Vice President of Worldwide Commercial Operations and Business Development.



JEFF RICCHETTI

PRESIDENT
RICCHETTI, INC.

Jeff Ricchetti is co-founder of Ricchetti, Inc. In his 35 years as an attorney and federal lobbyist, Mr. Ricchetti has developed an extensive background in health, tax, insurance, intellectual property and pharmaceutical issues. Mr. Ricchetti has been a lobbyist and consultant for Podesta & Mattoon, Ricchetti & Associates, and Public Strategies Washington. Mr. Ricchetti has also lobbied on health and tax issues for the Blue Cross Blue Shield Association and served as the organization's Director for Legislative Affairs. Mr. Ricchetti has represented a variety of national trade associations, Fortune 500 companies, and health professionals.



MICHAEL RINCK

FOUNDER AND MANAGING DIRECTOR
MT PROMEDT

Michael is the founder and managing director of MT Promedt Consulting GmbH, a German regulatory consulting company. He has over 30 years of experience in the medical device and pharmaceutical industry. Specialised in regulatory affairs and quality management systems he has supported numerous CE certification projects for medical devices and IVD products. He is responsible as Safety Officer and PRRC for international EAR clients (European Authorized Representative), also under the new EU Regulations (MDR/IVDR). He is a licensed pharmacist and microbiologist.



KATELIN ROBERTS

CEO
LINELOGIC

Katelin has management and operations experience within various industries including; aerospace, food manufacturing, and technology. Although Katelin has managed large corporate departments with 130+ people and \$86M annually, her passion lies in contributing to the growth and success of small companies that aspire to affect change in the world and improve patient healthcare. In her downtime, you can find Katelin spending time with her family or fly fishing on local waters.

Safeguarding Global Health®

- with every test we complete.

Let us help you get your product to market.

Contact our team of experts today.

- BIOCOMPATIBILITY
- CHEMICAL CHARACTERIZATION
- REUSABLE DEVICES
- STERILIZATION VALIDATION
- PACKAGING VALIDATION
- LOT RELEASE
- EXTRACTABLES & LEACHABLES

Sales Europe +32 16 40 04 84 | InfoEurope@Nelsonlabs.com
Sales US +1 801-290-7502 | Sales@NelsonLabs.com

www.NelsonLabs.com

FDA Registered ISO 17025



Nelson Labs®

A Sotera Health company



HEREDIGENE®: POPULATION STUDY

Protect your health and the health of generations to come.

Participate voluntarily and at no cost to you.



Sign up now at
heredigene.org/protectourhealth





TARA SAUCEDO

SR. DIRECTOR OF OPERATIONS
STRYKER

Dynamic supply chain executive with 20+ years of success providing value in global business environments. Professional experience includes supply chain operations, manufacturing, manufacturing transfer, S&OP, materials planning and inventory management, field service, IT systems implementation, LEAN/6 Sigma process improvement, medical device quality/regulatory compliance and developing teams.



JEFFREY SHUREN

DIRECTOR, CDRH
FDA

Jeffrey Shuren, MD, JD is the Director of the Center for Devices and Radiological Health (CDRH) at FDA. He previously served as Acting Center Director. Dr. Shuren has held various policy and planning positions within FDA from 1998 to 2009, including Acting Deputy Commissioner for Policy, Planning, and Budget; Associate Commissioner for Policy and Planning; and Special Counsel to the Principal Deputy Commissioner. Dr. Shuren is board certified in Neurology and served as an Assistant Professor of Neurology at the University of Cincinnati. In 1998, Dr. Shuren joined FDA as a Medical Officer in the Office of Policy. In 2000, he served as a detailee on the Senate HELP Committee. In 2001, he became the Director of the Division of Items and Devices in the Coverage and Analysis Group at the Centers for Medicare and Medicaid Services. From 1998 to 2003, he


served as a Staff Volunteer in the National Institutes of Health's National Institute of Neurological Disorders and Stroke Cognitive Neuroscience Section supervising and designing clinical studies on human reasoning. Dr. Shuren returned to FDA as the Assistant Commissioner for Policy in 2003, and assumed his current position in September 2009.



LAUREN SHURMAN

PARTNER
STOEL RIVES

Lauren is a litigation partner at Stoel Rives LLP, where she represents employers in matters relating to employment discrimination, harassment, wrongful termination, the Family Medical Leave Act, privacy issues, and non-compete agreements and trade secret law. She regularly advises clients on personnel policies and has assisted employers in developing employee handbooks, executive employment agreements, severance agreements, and non-compete agreements. Lauren also handles complex commercial litigation matters for businesses on issues ranging from breach of contract to tort claims. Lauren is currently President of the Salt Lake County Bar Association and has been recognized as one of "America's Leading Lawyers for Business" (Utah) by Chambers USA (Litigation: General Commercial) and as a Mountain States Super Lawyer® (Business Litigation).



GET MORE...

DONE IN CONTRACT MANUFACTURING

Vertically Integrated | Contract Manufacturing



LOCATIONS

Utah | Minneapolis | Texas | Indiana | Connecticut | Costa Rica



BIOMERICS • www.biomerics.com
 Corporate Headquarters
 6030 W Harold Gatty Dr, Salt Lake City, UT 84116 USA
 801.355.2705

© 2020 Biomerics LLC
 All rights reserved.

Biomerics is committed to innovation and leadership by providing leading-edge contract manufacturing services for the diagnostic and interventional markets in both the medical device and biotech industries. Our phase-gate development process focuses on manufacturing next-generation ideas and turning them into tangible, working solutions for the healthcare industry. Biomerics manages 6 locations, including facilities in Utah, Minnesota, Texas, Connecticut, Indiana, and Costa Rica.



BRANDI SIMPSON

BOARD CHAIR
BIOUTAH

Navigen’s board of directors elected Brandi to be chief executive officer effective April 2014. She was Navigen’s first official employee, and from 2007 until her promotion to CEO she served as chief business officer of the company. Prior to joining Navigen, she held senior positions in business development, corporate strategy, and investor relations at NPS Pharmaceuticals, where she negotiated and closed multiple licensing transactions and led the company’s portfolio review and strategic decision-making processes. In her last year at NPS, she also served as the head of investor relations. Prior to joining NPS, Brandi was director of business development at Emergen, a Utah genetics start-up. She was also a life sciences management consultant at Booz Allen & Hamilton, where she advised clients on a variety of business and strategic issues including mergers and acquisitions, post-merger integration and development of new business ventures. She began her career as an investment banking analyst at Merrill Lynch, where she worked on multiple public debt and equity financing transactions, structured financings, and mergers and acquisitions. Brandi graduated summa cum laude from the University of Utah with an honors degree in Finance. She earned an MBA degree at Stanford University’s Graduate School of Business.



GREGG SYLVESTER

CHIEF MEDICAL OFFICER & HEAD OF MEDICAL AFFAIRS

SEQIRUS – A CSL COMPANY

Dr. Gregg Sylvester has led Seqirus Medical Affairs since 2016, overseeing the global team that scientifically differentiates our vaccines by generating Real World Evidence and presenting Seqirus research to national vaccine recommending organizations. Gregg has extensive experience in the pharmaceutical industry, government and patient care. Prior to joining Seqirus, he led Medical Affairs teams in the worldwide launches of Gardasil, Prevnar 13 and Trumenba. Gregg obtained specialty boards in Pediatrics and General Preventive Medicine. Augmenting his clinical expertise, he served in the CDC Epidemic Intelligence Service and as a Public Policy Fellow in the U.S. Congress. During his distinguished career in state government, Gregg was appointed to the Cabinet Secretary for Health and Social Services in Delaware, leading the state’s largest agency. Gregg has a MD from Albany Medical College and an MPH from the Johns Hopkins Bloomberg School of Public Health.



GEETA VEMURI
MANAGING PARTNER
AGENT CAPITAL

Geeta Vemuri, PhD, MBA is a healthcare executive with unique experience in both Fund management and big pharma. Dr. Vemuri is the Founder of Agent Capital (2017), a Healthcare Venture Fund with focus on therapeutics investments in the areas of Oncology, Immunology and Rare Diseases. Current investors in the fund include, a strategic investor, family offices of former Pharma executives and institutional investors. Dr. Vemuri's fund responsibilities include, Firm management and portfolio management including deal negotiation, active company management through board role. Prior to Founding Agent Capital, Dr. Vemuri was Managing Partner of Baxter/Baxalta Ventures from 2012-2016, with over \$300M under management where she set strategy and executed on all aspects of management of the capital and was investment committee member. Prior to this she was Partner at Quaker Partners with focus on therapeutics and diagnostic investments. She started her business career at Salomon Smith Barney as Associate Specialty Pharma Analyst. She is a Kauffman Fellow Mentor (since 2018). Under her leadership Baxter ventures was named as top 6 Corporate healthcare VC Groups by Silicon Valley Bank (2015). She has a PhD in biochemistry from Indian Institute of Sciences and an MBA in Finance from Wharton School at the University of Pennsylvania.



SPENCER WALKER, MSC
DIRECTOR OF REGULATORY AFFAIRS
CENTER FOR MEDICAL INNOVATION,
UNIVERSITY OF UTAH

Spencer has over 20 years of medical industry experience, including 12 years in the Medical Device space as a Regulatory Affairs and Quality expert. Spencer has consulted for over 50 medical companies and design groups, and is currently at the 'spear-tip' of innovation as a consultant for the Center for Medical Innovation (U of U) and for Industry (Mountain Pacific Regulatory Consulting). Spencer earned a Master's degree in Translational Medicine from Cranfield University (UK).

EXHIBITORS

VISIT THE VIRTUAL BOOTH OF THE EXHIBITORS LISTED BELOW TO WIN VISA GIFT CARDS VALUED AT \$100, \$50, AND \$25.





THE MORE WE
REPRESENT THE WORLD,
THE MORE WE MOVE
HEALTH CARE FORWARD.

University of Utah Health believes society thrives when we give those who have been historically excluded the opportunity to succeed and live a healthy life. + Here, it begins by ending racism and bias in our workplaces because health care performs at its best when equity, diversity, and an inclusive employee community become an essential part of our mission. + We're bringing it to life with the addition of a Senior Director of Equity, Inclusion, and Diversity to our Human Resources Team. + We're reimagining our hiring programs to build pipelines for people of color to establish careers with us. + We're keeping dollars in our community to create jobs and help rebuild oppressed economies. + And we're listening to colleagues and patients of color to learn from their experiences.

At U of U Health, we're committed to being advocates and partners in the change we all want to see in the world.



HEALTH
UNIVERSITY OF UTAH

ELITE MEMBERS

LEGACY MEMBERS



PLATINUM MEMBERS




GOLD MEMBERS

SILVER MEMBERS



BRONZE MEMBERS



BIOUTAH MEMBERS

24 Proof
Abulus, Inc.
Advanced Quality System Solutions
Alcami
Alterra Medical
Alucent Biomedical, Inc.
American West Analytical Labs
Ampleo
Arrien Pharmaceuticals
ARUP Laboratories, Inc.
ATL Technology
Attostat, Inc.
Ballard Spahr
Bard Access Systems
Bastion Biologics
BioFire Diagnostics LLC
Biomerics
BioPharm Laboratories LLC
BioUtah
Brandwood CKC
BraveHeart Wireless, Inc.
BYU Technology Transfer Office
Carterra, Inc.
CG Research LLC
Cibus Biotechnology
Clene Nanomedicine, Inc.
Clinical Innovations
Co-Diagnostics Inc
Constant Therapeutics, LLC
Control - Distal Access
Counted, LLC
Crocker Ventures
Curavit Clinical Research
Curza
Deseret Labs
Dinesh and Kalpana Patel Foundation
DiscGenics
Diversified Insurance Group
Dynatronics Corporation
Echelon Biosciences, Inc.
Edwards Lifesciences LLC
ELLTechGroup
Epitel
Epurines, Inc
Espiritu
Esplin Biotechnology
Extreme Motus
FFKR Architects
Fluidx Medical Technology
Foldax
Fresenius Medical Care
FutraMed, Inc.
GE Healthcare Surgery
Genentech
GeneSTAT Molecular Diagnostics
Greg Gunn At Colliers International
gw Saar
Holland & Hart LLP
Horizon Therapeutics
IDbyDNA Inc
Inherent Biosciences Inc
InnovaBio & STUDENTfacturED
Intermountain Healthcare
Intermountain Life Sciences
InviRx
IONIQ Sciences, Inc.
iVeena Delivery Systems Inc.
J3 Bioscience, Inc.
JBR Clinical Research LLC
Jeffrey J. Kimbell & Associates
Johnson & Johnson
JPMorgan
Jsk Therapeutics Inc
KDT, Inc.
Kimball Electronics Inc.
Klean Katch
Leonhardt's Launchpads Utah, Inc.
Light Line Medical, Inc.
Majelco Medical Inc.
Mark E. Lundgren PC
Maschoff Brennan PLLC
MasterControl Inc.
Med Venture Holdings
MedForums, Inc.
Medic Life
MedLite ID
Merck
Merit Medical Systems, Inc.
Messner Reeves LLP
MT Promedt Consulting GmbH
Myriad Genetics, Inc.
Nelson Laboratories, LLC
Nexus Spine LLC
Novartis
Novo Nordisk
NOWCFO - Chris Badger
NuView Life Sciences
OPTIM Associates, Inc
Park City Angels
Partners for Innovation, Venture,
Outreach & Technology (PIVOT) Center
PEEL Therapeutics, Inc.
Pfizer
Phoenix PharmaLabs Inc
PhotoPharmics
PhRMA
PolarityTE
Price Real Estate
Progenitor Life Sciences
PROTECS
PwC
Quansys Biosciences Inc.
Recursion Pharmaceuticals
ReddyPort
RefloDx
Renalytix AI
Rosivo Inc
Salt Lake City Corporation Department
of Economic Development
SANOFI
Schwegman Lundberg & Woessner
Scintillant Bioscience, LLC
SciSafe
SDP Oncology
Sera Prognostics
Serfwerks
Signpath Pharma
Silverstone Automation
Simpson Thacher & Bartlett LLP
SINTX Technologies, Inc.
Snell & Wilmer, LLP
Soft Cell Biological Research, LLC
Sorenson Forensics
Spectrum Solutions
Sports Medicine Research and Testing
Lab
Squire & Company, P.C.
Stoel Rives LLP
StratusHR
Stryker
SymbioCellTech
Teva Pharmaceuticals
The Bracken Group
The Gateway - Vestar
The Hennessy Group, Inc.
The Kenney Group
The KPI System
TherapEase Innovation LLC
Through the Cords, LLC
Thunder Biotech, Inc
Turner MedTech, Inc
Ultradent Products
University of Utah
Utah State University, Technology
Transfer Services
Varex Imaging Corporation
Vertex Pharmaceuticals
Weild & Co.
Wilson Sonsini Goodrich & Rosati
Workman Nydegger
Xenacor
Xenter, Inc.
Zenerchi LLC
ZIEN Medical Technologies, Inc

UTAH'S PREMIER EVENT FOR INVESTMENT IN THE LIFE SCIENCES



ENTREPRENEUR AND INVESTOR LIFE SCIENCE SUMMIT 2021

FEBRUARY 25-26, 2021



Powered by BIO

Your Pathway to Partnerships

BIO ONE-ON-ONE PARTNERING™

is the most cost-effective, efficient way to make valuable connections in the biotech and pharma industry without traveling the world.

Communicate directly with prospective biotech investors and senior business and scientific management executives attending BIO's portfolio of events.

bio.org/events →

BIO is setting the partnering agenda in a semi-virtual BD world...JOIN US.

	October 13-15 2020
NEURO SCIENCE:	November 2-4 2020
INFECTIOUS DISEASES:	December 2-4 2020
	January 11-14 2021
	February 16-18 2021



BIO members receive discounts on registration, company presentations, and exhibition fees at all of our conferences and events.